FDA approves first medical device for obesity treatment targeting brain-to-stomach signaling

15 enero 2015

The United States Food and Drug Administration (FDA) approved EnteroMedic’s VBLOC® vagal blocking therapy, delivered via the Maestro® System, which is the first medical device approved for obesity treatment that targets the nerve pathway between the brain and the stomach. The Obesity Society calls this a «a novel device that interrupts signals from the stomach to the brain that are believed to be involved with stomach emptying and feelings of fullness.»
http://feeds.sciencedaily.com/~r/sciencedaily/~3/5y0_CTeQT_g/150115122015.htm

Volver